Saturday 17 October 2026
Export CRBU’s income statement to Excel — free account
Caribou Biosciences, Inc.
CRBU Healthcare Biotechnology
Caribou Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 million, up 11.7% from fiscal 2024. In the quarter to June 2026, revenue fell 43.8%, EPS grew 58.6% and free cash flow fell 33.2%, each against the same quarter a year earlier.
0.47
0.00
0.00%
Follow CRBU
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 3 | 3 |
| (74.28%) | (78.97%) | (83.46%) | (78.27%) | ||
| (58.27%) | (60.62%) | (63.04%) | (56.87%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(116.35%) | (117.02%) | (122.41%) | (99.31%) | |
Average Days of Receivables |
81.29 | 64.53 | 54.47 | 48.67 | |
Free Cash Flow per Share |
(1.37) | (1.20) | (1.06) | (1.31) | |
Free Cash Flow |
(127.72) | (112.35) | (101.64) | (132.79) | |
Capital Expenditures |
(2.08) | (1.36) | (0.39) | (37.01) | |
| Other line items | |||||
Cash ROIC |
(44.18%) | (42.96%) | (46.27%) | (63.11%) | |
Accounts Receivable Turnover |
4.72 | 5.49 | 6.22 | 5.96 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,248.93% | 980.72% | 843.69% | 854.70% | |
Selling, General and Administrative Expense of Revenue |
428.43% | 339.76% | 323.53% | 336.20% | |
Share Based Compensation of Revenue |
149.04% | 113.63% | 99.57% | 104.66% | |
Operating CF/Net income |
0.80 | 0.75 | 0.76 | 0.93 | |
Depreciation/Fixed assets |
0.28 | 0.37 | 0.35 | 0.34 | |
Capex/Depreciation |
(0.97) | (0.54) | (0.18) | (19.70) | |
Revenue per Share |
0.10 | 0.12 | 0.12 | 0.10 | |
Operating CF per Share |
(1.35) | (1.19) | (1.06) | (0.95) | |
Capex per Share |
(0.02) | (0.01) | 0.00 | (0.37) | |
Capex to Sales |
0.22 | 0.12 | 0.03 | 3.69 |
Columns are period end dates